Showing results (71-80 of 76) with videos related to
Sort By:
Pageof 8
You have reached the last page of results.This site can display upto 76 results.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|March 27, 2021
Symptom Diaries of Patients with Midgut Neuroendocrine Tumors Treated with 177Lu-DOTATATEJonathan R Strosberg, Rajaventhan Srirajaskanthan, Ghassan El-Haddad, et al.British Journal of Cancer|November 26, 2022
Dual [68Ga]DOTATATE and [18F]FDG PET/CT in patients with metastatic gastroenteropancreatic neuroendocrine neoplasms: a multicentre validation of the NETPET scoreDavid L Chan, Aimee R Hayes, Ioannis Karfis, et al.Neuroendocrinology|September 25, 2018
Unmet Medical Needs in Pulmonary Neuroendocrine (Carcinoid) NeoplasmsEric Baudin, Aimee R Hayes, Jean-Yves Scoazec, et al.Clinical Therapeutics|May 5, 2018
Changes in Weight Associated With Telotristat Ethyl in the Treatment of Carcinoid SyndromeMartin O Weickert, Gregory Kaltsas, Dieter Hörsch, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 6, 2016
Telotristat Ethyl, a Tryptophan Hydroxylase Inhibitor for the Treatment of Carcinoid SyndromeMatthew H Kulke, Dieter Hörsch, Martyn E Caplin, et al.The Lancet. Oncology|November 18, 2021
177Lu-Dotatate plus long-acting octreotide versus high‑dose long-acting octreotide in patients with midgut neuroendocrine tumours (NETTER-1): final overall survival and long-term safety results from an open-label, randomised, controlled, phase 3 trialJonathan R Strosberg, Martyn E Caplin, Pamela L Kunz, et al.Pageof 8